sutent 12.5 mg hard capsules
pfizer - sunitinib - hard gelatin capsules - 12.5 mg - antineoplastic agents - sunitinib is indicated for the treatment of gastrointestinal stromal tumor (gist) after failure of imatinib mesylate treatment due to resistance or intolerance. sunitinib is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (mrcc). sunitinib is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (pnet) with disease progression.
sutent 50mg capsules
pfizer ltd - sunitinib malate - capsule - 50mg
sutent 25mg capsules
pfizer ltd - sunitinib malate - capsule - 25mg
sutent 12.5mg capsules
pfizer ltd - sunitinib malate - capsule - 12.5mg
sunitinib aqvida capsules hard 25mg
aqvida gmbh kaiser-wilhelm-str 89, 20355 hamburg, germany - sunitinib - hard capsule - sunitinib 25 mg - antineoplastic agents
sunitinib aqvida capsules hard 37.5mg
aqvida gmbh kaiser-wilhelm-str 89, 20355 hamburg, germany - sunitinib - hard capsule - sunitinib 37.5 mg - antineoplastic agents
sunitinib aqvida capsules hard 50mg
aqvida gmbh kaiser-wilhelm-str 89, 20355 hamburg, germany - sunitinib - hard capsule - sunitinib 50 mg - antineoplastic agents
sunitinib aqvida capsules hard 12.5mg
aqvida gmbh kaiser-wilhelm-str 89, 20355 hamburg, germany - sunitinib - hard capsule - sunitinib 12.5 mg - antineoplastic agents
maxinib 12.5mg hard capsules
boston biopharma limited malta life sciences park, building 2, level 0, san gwann sgn 3000, malta - sunitinib - hard capsule - sunitinib 12.5 mg - antineoplastic agents
maxinib 25mg hard capsules
boston biopharma limited malta life sciences park, building 2, level 0, san gwann sgn 3000, malta - sunitinib - hard capsule - sunitinib 25 mg - antineoplastic agents